FDA Warning Letter – CanAmerica Global

10903 New Hampshire Avenue
Silver Spring, MD 20993

 

TO:        CanAmerica Global
FROM: The United States Food and Drug Administration
RE:        Notice of Unlawful Sale of Unapproved and Misbranded Drug Products to United States Consumers over the Internet
DATE:   September 19, 2017
WARNING LETTER
The United States (U.S.) Food and Drug Administration (FDA) recently reviewed your websites (listed at the bottom of this letter) and determined that they offer products for sale in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act). More specifically, the websites listed below offer unapproved new drugs and misbranded drugs for sale in U.S. commerce in violation of sections 301(a), 301(d), 503(b), and 505(a) of the FD&C Act [21 U.S.C. §§ 331(a), 331(d), 353(b), and 355(a)]. FDA requests that you immediately cease marketing violative drug products to U.S. consumers.
Unapproved New Drugs
 
As labeled, certain products offered for sale through your websites are drugs within the meaning of section 201(g) of the FD&C Act [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and/or because they are intended to affect the structure or function of the body. These products, as marketed through your websites, are also new drugs as defined by section 201(p) of the FD&C Act [21 U.S.C. § 321(p)], because they are not generally recognized as safe and effective for their labeled uses. New drugs may not be introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&C Act [21 U.S.C. § 355(a)]. No approved applications pursuant to section 505 of the FD&C Act [21 U.S.C. § 355] are in effect for these products. Accordingly, their introduction or delivery for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act [21 U.S.C. §§ 331(d) and 355(a)].
An example of an unapproved drug on your websites is injectable epinephrine marketed as “Allerject.” While there is an FDA-approved version of injectable epinephrine on the market in the U.S. offered as “EpiPen,” the product offered for sale on your websites is not the FDA-approved product. There is currently no approved application pursuant to section 505 of the FD&C Act [21 U.S.C. § 355] in effect for “Allerject,” the epinephrine product offered for sale on your websites. Moreover, particularly concerning is that all Allerject devices in Canada were the subject of a nationwide recall in 2015 due to a drug delivery concern associated with a device malfunction. FDA-approved “EpiPen” is a prescription drug used to treat allergic emergencies (anaphylaxis) due to stinging or biting insects, foods, drugs, exercise, or unknown causes.  Offering this unapproved new drug on your websites is particularly concerning given that even FDA-approved epinephrine products are associated with significant risks including warnings regarding serious infections at the injection site and use in patients with heart disease.
 
 
Misbranded Drugs
A drug is misbranded under section 502(f)(1) of the FD&C Act [21 U.S.C. § 352(f)(1)] if it fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the FD&C Act [21 U.S.C. § 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.
 “Allerject” is an unapproved new drug under the FD&C Act as described above. Because the aforementioned drug is a prescription product intended for condition(s) that are not amenable to self-diagnosis and treatment by a layperson, adequate directions cannot be written such that a layperson can use the product safely for its intended use(s). Consequently, the labeling for this product fails to bear adequate directions for its intended use(s), causing it to be misbranded under section 502(f)(1) of the FD&C Act [21 U.S.C. § 352(f)(1)]. Because “Allerject” lacks the required FDA approved application, it is not exempt under 21 CFR 201.115 from the requirements of section 502(f)(1) of the FD&C Act. By offering this drug for sale to U.S. consumers, your websites are causing the introduction of misbranded drugs into interstate commerce in violation of section 301(a) of the FD&C Act [21 U.S.C. § 331(a)].
***
FDA is taking this action against CanAmerica Global because of the inherent risk to consumers who purchase unapproved new drugs and misbranded drugs. Unapproved new drugs do not have the same assurance of safety and effectiveness as those drugs subject to FDA oversight, and drugs that have circumvented regulatory safeguards may be contaminated, counterfeit, contain varying amounts of active ingredients, or contain different ingredients altogether.
This letter is not intended to identify all the ways in which your activities might be in violation of law. It is your responsibility to ensure that all products you market are in compliance with the FD&C Act and its implementing regulations.  You should take prompt action to correct the violations noted above as well as any other violations of the FD&C Act (which would include the offer for sale of all unapproved and/or misbranded drug products by your websites, not just the products noted above).  Failure to correct violations may result in FDA regulatory action, including seizure or injunction, without further notice.
Please notify this office in writing within 10 working days of receipt of this letter of any steps you have taken or will take to correct the violations set forth above and to prevent their recurrence.
If the corrective action(s) cannot be completed within 10 working days, state the reason for the delay and the time within which the correction(s) will be completed. Your response and any other inquiries concerning this letter should be sent to FDA’s Internet Pharmacy Task Force at FDAInternetPharmacyTaskForce-CDER@fda.hhs.gov.
 
Table of Websites:
 
Connecting URL
locuspharma.com
greyspharmacy.com
77canada.com
genericdrugoutlet.com
pharmadd.com
pricechoprx.com
travantipharma.com
77canadapharmacy.com
77canadapharmacy.net
bestindiapharmacy.com
buckadaypharmacy.com
bulkdrugsonline.com
canadapharmacyselect.com
canadian-pharmacies-online.net
canamerica.com
canamericadrugs.com
canamericaglobal.com
canamericaglobal.net
discountvaluemeds.com
freeshippingmedication.com
genericdrugsuperstore.com
libertydiscountdrugstore.com
medcentercanada.net
medsearchonline.com
panthermeds.net
pioneerfund.org
realfastdrugstore.net
rfdrugstore.net
worldwidedrugplan.com
americanameds.com
medcentercanada.com
rfdrugstore.com
thedrugcompany.com
Sincerely,
/s/
Thomas Christl
Director
Office of Drug Security, Integrity, and Response
Office of Compliance
Center for Drug Evaluation and Research
Food and Drug Administration

Leave a Comment

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s